Allergy Therapeutics PLC Publication of Annual Report and notice of AGM (1267U)
October 19 2017 - 11:14AM
UK Regulatory
TIDMAGY
RNS Number : 1267U
Allergy Therapeutics PLC
19 October 2017
19 October 2017
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
ANNUAL FINANCIAL REPORT 2017 AND NOTICE OF 2017 ANNUAL GENERAL
MEETING
Allergy Therapeutics Plc has today published the following
documents:
-- Annual Report for the year ended 30 June 2017 ("Annual Report"); and
-- Notice of 2017 Annual General Meeting ("Notice of Meeting");
Each of these documents is available electronically on the
Company's website at www.allergytherapeutics.com
A hard copy of the Annual Report and Notice of Meeting is
anticipated to be posted to shareholders on 19 October 2017.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Philippa Gardner
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical group focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.500 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBUBDGDBBBGRC
(END) Dow Jones Newswires
October 19, 2017 11:14 ET (15:14 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024